Shares of Avinger Inc (NASDAQ:AVGR) hit a new 52-week low on Wednesday . The stock traded as low as $0.19 and last traded at $0.20, with a volume of 1764600 shares traded. The stock had previously closed at $0.22.

The firm has a market cap of $6.15 and a price-to-earnings ratio of -0.09.

In other news, insider John B. Ph D. Md Simpson sold 1,074,130 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $0.25, for a total transaction of $268,532.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman John B. Ph D. Md Simpson sold 454,584 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $0.27, for a total value of $122,737.68. The disclosure for this sale can be found here. Insiders own 17.00% of the company’s stock.

An institutional investor recently bought a new position in Avinger stock. AWM Investment Company Inc. bought a new position in shares of Avinger Inc (NASDAQ:AVGR) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 1,150,000 shares of the medical device company’s stock, valued at approximately $516,000. AWM Investment Company Inc. owned 4.81% of Avinger at the end of the most recent quarter. Institutional investors own 3.79% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Avinger (AVGR) Sets New 1-Year Low at $0.19” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at

Avinger Company Profile

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with's FREE daily email newsletter.